Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Notes Payables (2016 - 2018)

Historic Notes Payables for Tg Therapeutics (TGTX) over the last 3 years, with Q4 2018 value amounting to $67000.0.

  • Tg Therapeutics' Notes Payables fell 4765.62% to $67000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $67000.0, marking a year-over-year decrease of 4765.62%. This contributed to the annual value of $67000.0 for FY2018, which is 4765.62% down from last year.
  • Tg Therapeutics' Notes Payables amounted to $67000.0 in Q4 2018, which was down 4765.62% from $91000.0 recorded in Q3 2018.
  • In the past 5 years, Tg Therapeutics' Notes Payables ranged from a high of $224000.0 in Q1 2018 and a low of $67000.0 during Q4 2018
  • For the 3-year period, Tg Therapeutics' Notes Payables averaged around $138238.6, with its median value being $140284.0 (2017).
  • In the last 5 years, Tg Therapeutics' Notes Payables soared by 8584.39% in 2017 and then crashed by 5004.28% in 2018.
  • Quarter analysis of 3 years shows Tg Therapeutics' Notes Payables stood at $68875.0 in 2016, then soared by 85.84% to $128000.0 in 2017, then tumbled by 47.66% to $67000.0 in 2018.
  • Its Notes Payables was $67000.0 in Q4 2018, compared to $91000.0 in Q3 2018 and $210000.0 in Q2 2018.